ProPhase Labs (PRPH)
(Delayed Data from NSDQ)
$2.40 USD
-0.05 (-2.04%)
Updated Sep 16, 2024 04:00 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
ProPhase Labs, Inc. [PRPH]
Reports for Purchase
Showing records 21 - 40 ( 51 total )
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Chemotherapy Enhancer Advances in Preclinical Studies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Novel Esophageal Cancer Test Acquired; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
3Q22 Financial Results Reported; Reiterate Buy; Modulating PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Collaboration Inked to Drive Genomic Sequencing Business; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Novel Cancer Compounds In-Licensed; Stock Repurchase Authorized; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Is ProPhase Now an Oncology Company? If You Read The Press Release ? What?s a Co-Therapy? Lowering Our Rating from Neutral to Sell
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
ProPhase BioPharma Established for Development of Novel Drugs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Laboratory and Clinical Testing Capabilities Expanded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
New Record Performance in 1Q22; Reiterate Buy; Modulating PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Buy: Reiterate Buy, Raise Price Target to $2.00
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Record Performance in 2021; Reiterate Buy; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
A Special Dividend? Sounds Nice but Does it Make Sense?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Record Testing Volume in 4Q21; Reiterate Buy; Raise PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Company: ProPhase Labs, Inc.
Industry: Medical - Drugs
Lowering to Neutral - ProPhase Preannounces Another Miss
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J